From modern pathogenetic insights and molecular understanding to new deescalating therapeutic strategies in gastric MALT-lymphoma

Wolfgang Fischbach; Matthias Eck; Andreas Rosenwald

doi:10.1055/a-2382-7820

Zeitschrift für Gastroenterologie, Table of Contents

Z Gastroenterol 2024; 62(11): 1952-1962
DOI: 10.1055/a-2382-7820

Übersicht

From modern pathogenetic insights and molecular understanding to new deescalating therapeutic strategies in gastric MALT-lymphoma

30 years’ experience with Helicobacter pyloriVon modernen pathogenetischen Erkenntnissen und molekularem Verständnis zu neuen deeskalierenden Therapiestrategien bei gastralen MALT-Lymphomen30 Jahre Erfahrung mit Helicobacter pylori

Wolfgang Fischbach

¹Gastroenterologische Gemeinschaftspraxis Aschaffenburg, Klinikum Aschaffenburg-Alzenau, Academic Teaching Hospital of the University of Würzburg, Aschaffenburg, Germany

,

Matthias Eck

²Institute of Pathology, Klinikum Aschaffenburg-Alzenau, Academic Teaching Hospital of the University of Würzburg, Aschaffenburg, Germany

,

Andreas Rosenwald

³Institute of Pathology, University of Würzburg, Würzburg, Germany

› Author Affiliations

Abstract

Based on new insights into the aetiology and pathogenesis of gastric marginal-zone B-cell lymphoma of MALT (MALT-lymphoma) and its histomorphological and molecular characteristics, important progress in our understanding of the disease and its clinical management has been made during the last decades. A landmark in this development was the identification of Helicobacter pylori as the decisive pathogenetic factor for gastric MALT lymphoma. We, here, give an overview about the history and the current knowledge of the histology, genetics, and molecular characteristics and pathogenesis of gastric MALT lymphoma. We then focus on how these findings have fundamentally changed its clinical management over the last three decades with consequent deescalating therapeutic strategies.

Zusammenfassung

Ausgehend von neuen Einsichten in die Ätiologie und Pathogenese gastraler Marginalzonen-B-Zell-Lymphome des MALT (MALT-Lymphome) und ihrer histomorphologischen und molekularen Charakteristika hat sich unser Verständnis der Erkrankung in den letzten Jahrzehnten erheblich verbessert und das klinische Management beeinflusst. Ein Meilenstein in dieser Entwicklung war die Entdeckung des Helicobacter pylori als entscheidender Risikofaktor für gastrale MALT-Lymphome. Wir präsentieren hier einen Überblick über die Geschichte und den aktuellen Kenntnisstand zu Histologie, Genetik, molekularen Charakteristika und Pathogenese der gastralen MALT-Lymphome. Danach fokussieren wir darauf, wie diese Erkenntnisse fundamental das klinische Management über die letzten drei Jahrzehnte verändert und konsequent zu deeskalierenden Therapiestrategien geführt hat.

Keywords

gastric MALT lymphoma - Helicobacter pylori - pathogenesis - histology - genetics - clinical management

Schlüsselwörter

Gastrale MALT-Lymphome - Helicobacter pylori - Pathogenese - Histologie - Genetik - klinisches Management

Full Text

References

References
1 Fischbach W, Kestel W, Kirchner Th. et al. Malignant lymphoma of the upper gastrointestinal tract. Results of a prospective study in 103 patients. Cancer 1992; 70: 1075-1108
2 Rappaport H. Tumors of the hematopoietic system. In: Atlas of Tumor Pathology, Section 3, Fascicle 8. Washington, DC: US Armed Forces Institute of Pathology; 1966
3 Lukes RJ, Collins RD. Immunologic characterization of human malignant lymphomas. Cancer 1974; 34: 1488-1503
4 Lennert K, Mohri N. Histopathology and diagnosis of non-Hodgkin’s lymphomas. In: Malignant Lymphomas Other than Hodgkin´s Disease. New York: Springer-Verlag; 1978: 111-469
5 The non-Hodgkin’s lymphoma pathological classification project. National Cancer Institute sponsored study of classifications of non-Hodgkin’s lymphomas. Cancer 1982; 49: 2112-2135
6 Dawson IMP, Cornes JS, Morson BC. Primary malignant lymphoid tumors of the intestinal tract: report of 37 cases with a study of factors influencing prognosis. Br J Surg 1961; 49: 80-89
7 Lewin KJ, Ranchod M, Dorfman RF. Lymphomas of the gastrointestinal tract – A study of 117 cases presenting with gastrointestinal disease. Cancer 1978; 42: 693-707
8 Hermann R, Panahon AM, Barcos MP. et al. Gastrointestinal Involvement in Non-Hodgkin’s Lymphoma. Cancer 1980; 46: 215-222
9 Harris NL, Jaffe ES, Stein H. et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392
10 Isaacson PG, Wright DH. Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer 1983; 52: 1410-1416
11 Isaacson PG, Spencer J. Malignant lymphoma of mucosa associated lymphoid tissue. Histopathology 1987; 11: 445-462
12 Isaacson PG, Spencer J, Wright DH. Classifying primary gut lymphomas. Lancet 1988; 2: 1148-1149
13 Alaggio R, Amador C, Anagnostopoulos I. et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022; 36 (07) 1720-1748
14 Ullrich A, Fischbach W, Blettner M. Incidence of gastric B-cell lymphomas: a population-based study in Germany. Ann Oncol 2002; 13 (07) 1120-1127
15 Khalil MO, Morton LM, Devesa SS. et al. Incidence of marginal zone lymphoma in the United States, 2001–2009 with a focus on primary anatomic site. British Journal of Haematology 2014; 165: 67-77
16 Marshall BJ, Warren Jr. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancte 1983; 1: 1311-1315
17 Wyatt JI, Rathbone BJ. Immune response of the gastric mucosa to Campylobacter pylori. Scand J Gastroenterol 1988; 23 (Suppl. 142) 135-140
18 Stolte M, Eidt S. Lymphoid follicles in antral mucosa: immune response to Campylobacter pylori?. J Clin Pathol 1989; 1269-1271
19 Stolte M. Helicobacter pylori gastritis and gastric MALT-lymphoma. Lancet 1992; 339: 745
20 Wotherspoon A, Ortiz-Hidalgo C, Falzon MR. et al. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 1991; 338: 1175-1176
21 Eck M, Schmaußer W, Haas R. et al. MALT-type lymphoma of the stomach is associated with Helicobacter pylori strains expressing the CagA protein. Gastroenterology 1997; 112: 1482-1486
22 Doglioni C, Wotherspoon AC, Moschini A. et al. High incidence of primary gastric lymphoma in northeastern Italy. Lancet 1992; 339: 834-835
23 Parsonnet J, Hansen S, Rodriguez L. et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med 1994; 330: 1267-1271
24 Greiner A, Marx A, Heesemann J. et al. Idiotype identity in a MALT-type lymphoma and B-cells in Helicobacter pylori associated chronic gastritis. Lab Investigation 1994; 70: 572-578
25 Hussell T, Isaacson PG, Crabtree JE. et al. The response of cells from low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue to Helicobacter pylori. Lancet 1993; 342: 571-574
26 Hussell T, Isaacson PG, Crabtree JE. et al. Helicobacter pylori specific tumour infiltrating T-cells provide contact dependent help for the growth of malignant B-cells in low-grade gastric lymphoma of mucosa-associated lymphoid tissue. J Pathol 1996; 178: 122-127
27 Qin Y, Greiner A, Hallas C. et al. Intraclonal offspring expansion of gastric low-grade MALT-type lymphoma: evidence for the role of antigen-driven high-affinity mutation in lymphomagenesis. Lab Invest 1997; 76 (04) 477-485
28 Enno A, O’Rourke J, Howlett CR. et al. MALToma-Like Lesions in the Murine Gastric Mucosa after Long-Term Infection with Helicobacter felis. A Mouse Model of Helicobacter pylori-Induced Gastric Lymphoma. Am J Pathol 1995; 147: 217-222
29 Lee A, O’Rourke J, Enno A. Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: Implications of Animal Models on Pathogenic and Therapeutic Considerations – Mouse Models of Gastric Lymphoma. Gastrointestinal Lymphomas – Future perspectives. In: Recent Results in Cancer Research. Springer (editor Fischbach W) 2000; 156: 42-51
30 Wotherspoon A, Doglioni C, Diss TC. et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993; 342: 575-577
31 Zullo A, Hassan C, Cristofari F. et al. Effects of Helicobacter pylori Eradication on Early Stage Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. Clin Gastroenterol Hepatol 2010; 8: 105-110
32 Nakamura S, Delabie J. Extranodal marginal zone lymphoma of mucosa- associated lymphoid tissue (MALT lymphoma) involving the digestive tract. In: WHO Classification of Tumours. Digestive System Tumours. Lyon: IARC; 2019: 378-385
33 Cheuk Wah, Delabie J, Ott G. et al. Extranodal marginal zone lymphoma of mucosa-associated tissue. In WHO Classification of Tumours. In: Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2023
34 Papadaki L, Wotherspoon AC, Isacson PG. The lymphoepithelial lesion of gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue (MALT): an ultrastructural study. Histopathology 1992; 21 (05) 415-421
35 Zucca E, Arcaini L, Buske C. et al. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020; 31 (01) 17-29
36 Copie-Bergmann C, Gaulard P, Lavergne-Slove A. et al. Proposal for a new histological grading system for post-treatment evaluation of gastric MALT lymphoma. Gut 2003; 52: 1656-1659
37 Kanellis G, Roncador G, Arribas A. et al. Identification of MNDA as a new marker for nodal marginal zone lymphoma. Leukemia 2009; 23 (10) 1847-1857
38 Wang Z, Cook JR. IRTA1 and MNDA Expression in Marginal Zone Lymphoma: Utility in Differential Diagnosis and Implications for Classification. Am J Clin Pathol 2019; 151 (03) 337-343
39 Isaacson PG. The MALT lymphoma concept updated. Ann Oncol 1995; 6 (04) 319-320
40 Mazzucchelli L, Blaser A, Kappeler A. et al. BCA-1 is highly expressed in Helicobacter pylori-induced mucosa-associated lymphoid tissue and gastric lymphoma. J Clin Invest 1999; 104 (10) R49-R54
41 Deutsch AJA, Steinbauer E, Hofmann NA. et al. Chemokine receptors in gastric MALT lymphoma: loss of CXCR4 and upregulation of CXCR7 is associated with progression to diffuse large B-cell lymphoma. Mod Pathol 2013; 26 (02) 182-194
42 Isaza-Correa JM, Liang Z, van den Berg A. et al. Toll-like receptors in the pathogenesis of human B cell malignancies. J Hematol Oncol 2014; 12: 7-57
43 Adam P, Schmausser B, Göbeler-Kolve M. et al. Gastric extranodal marginal zone B-cell lymphomas of MALT type exclusively express Toll- like receptor 4 in contrast to other lymphomas infiltrating the stomach. Ann Oncol 2008; 19 (03) 566-569
44 Umehara S, Higashi H, Ohnishi N. et al. Effects of Helicobacter pylori CagA protein on the growth an survival of B lymphocytes, the origin of MALT- lymphoma. Oncogene 2003; 22 (51) 8337-8342
45 Zhu Y, Wang C, Huang J. et al. The Helicobacter pylori virulence factor CagA promotes Erk1/2-mediated Bad phosphorylation in lymphocytes: a mechanism of CagA-inhibited lymphocyte apoptosis. Cellular Microbiology 2007; 9 (04) 952-961
46 Lin WC, Tsai HF, Kuo SH. et al. Translocation of Helicobacter pylori CagA into Human B lymphocytes, the origin of mucosa-associated lymphoid tissue lymphoma. Cancer Res 2010; 70 (14) 5740-5748
47 Kuo SH, Yeh KH, Chen LT. et al. Helicobacter pylori CagA Translocation Is Closely Associated With the Expression of CagA-signaling Molecules in Low-grade Gastric Mucosa-associated Lymphoid Tissue Lymphoma. Am J Surg Pathol 2015; 39 (06) 761-766
48 Kuo SH, Chen LT, Lin CW. et al. Expressions of the CagA protein and CagA- signaling molecules predict Helicobacter pylori dependence of early-stage gastric DLBCL. Blood 2017; 129 (02) 188-198
49 Peng H, Ranaldi R, Diss TC. et al. High frequency of CagA+ Helicobacter pylori infection in high-grade gastric MALT B-cell lymphomas. J Pathol 1998; 185 (04) 409-412
50 Delchier JC, Lamarque D, Levy M. et al. Helicobacter pylori and gastric lymphoma: high seroprevalence of CagA in diffuse large B-cell lymphoma but not in low-grade lymphoma of mucosa-associated lymphoid tissue type. Am J Gastroenterol 2001; 96 (08) 2324-2328
51 Ye H, Liu H, Attygalle A. et al. Variable frequencies of t(11;18)(q21;q21) in MALT lymphomas of different sites: significant association with CagA strains of H pylori in gastric MALT lymphoma. Blood 2003; 102 (03) 1012-1018
52 Keikha M, Sahebkar A, Yamaoka Y. et al. Helicobacter pylori cagA status and gastric mucosa-associated lymphoid tissue lymphoma: a systematic review and meta-analysis. J Health Popul Nutr 2022; 41 (01) 2
53 Mendes LST, Attygalle A, Wotherspoon AC. Helicobacter pylori infection in gastric extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) lymphoma: a re-evaluation. Gut 2014; 63 (09) 1526-1527
54 Gu SX, Siddon AJ, Huntington SF. et al. Helicobacter pylori-negative mucosa- associated lymphoid tissue (MALT) lymphoma of the stomach: A clinicopathologic analysis. Am J Clin Pathol 2023; 160 (06) 612-619
55 Eck M, Greiner A, Schmaußer B. et al. Evaluation of Helicobacter-pylori in gastric MALT-type lymphoma: differences between histological and serological diagnosis and their implications for clinical therapy. Mod Pathol 1999; 12 (12) 1148-1151
56 Ye H, Liu H, Attygalle A. et al. Variable frequencies of t(11;18)(q21;q21) in MALT lymphomas of different sites: significant association with CagA strains of H pylori in gastric MALT lymphoma. Blood 2003; 102 (03) 1012-1018
57 Rosebeck S, Madden L, Jin X. et al. Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activation. Science 2011; 331: 468-472
58 Rodriguez-Sevilla JJ, Salar A. Recent Advances in the Genetic of MALT Lymphomas. Cancers 2021; 14 (01) 176
59 Liu H, Ye H, Ruskone-Fourmestraux A. et al. T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology 2002; 122 (05) 1286-1294
60 Hyeon J, Lee B, Shin SH. et al. Targeted deep sequencing of gastric marginal zone lymphoma identified alterations of TRAF3 and TNFAIP3 that were mutually exclusive for MALT1 arrangement. Mod Pathol 2018; 31 (09) 1418-1428
61 Raderer M, Kiesewetter B, Du MQ. Clinical relevance of molecular aspects in extranodal marginal zone lymphoma: a critical appraisal. Ther Adv Med Oncol 2023; 17588359231183565
62 Kolve M, Fischbach W, Greiner A. et al. Differences in endoscopic and clinicopathological features of primary and secondary gastric non-Hodgkin´s lymphoma. Gastrointest Endosc 1999; 49: 307-315
63 Ruskoné-Fourmestraux A, Fischbach W, Aleman BMP. et al. EGILS consensus report. Gastric extranodal marginal zone B cell lymphoma of MALT Gut 2011; 60: 747-758
64 Zucca E, Arvaini L, Buske C. et al. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020; 31 (01) 17-29
65 Flieger D, Keller R, May A. et al. Capsule endoscopy in gastrointestinal lymphoma. Endoscopy 2005; 37: 1174-1180
66 Fischbach W. Colorectal MALT lymphoma: a rare clinical entity. Experiences from a clinical series. Z Gastroenterol 2018; 56: 905-911
67 Musshoff K. Clinical staging classification of non-Hodgkin’s lymphomas. Strahlentherapie 1977; 153: 218-21
68 Radaszkiewicz Th, Dragosics B, Bauer P. Gastrointestinal malignant lymphomas of the mucosa-associated lymphoid tissue. Factors relevant to prognosis. Gastroenterology 1992; 102: 1628-1638
69 Ruskone-Fourmestraux A, Dragosics B, Morgner A. et al. Paris staging system for primary gastrointestinal lymphomas. Gut 2003; 52: 912-913
70 Fischbach W, Dragosics B, Koelve-Goebeler ME. et al. Primary gastric B-cell Lymphoma: Results of a Prospective Multicenter Study. Gastroenterology 2000; 119: 1191-1202
71 Koch P, delValle F, Berdel WE. et al. Primary Gastrointestinal Non-Hodgkin´s Lymphoma: I. Anatomic and Histologic Distribution, Clinical Features, And Survival Data of 371 Patients Registered in the German Multicenter Study GIT NHL 01/92. J Clin Oncol 2001; 19: 3861-3873
72 Koch P, Probst A, Berdel WE. et al. Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96). J Clin Oncol 2005; 23: 7050-7059
73 Tsang RW, Gospodarowicz MK, Pintilie M. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol 2003; 21: 4157-4164
74 Fischbach W, Schramm S, Goebeler E. Outcome and Quality of Life Favour a Conservative Treatment of Patients with Primary Gastric Lymphoma. Z Gastroenterol 2011; 49: 1-6
75 Cirochi R, Farinella E, Trastulli S. et al. Surgical treatment of primary gastrointestinal lymphoma. World J Surg Oncol 2011; 9: 145-151
76 Schechter NR, Portlock CS, Yahalom J. Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. J Clin Incol 1998; 16: 1916-1921
77 Sutcliffe SB, Gospodarowicz MK, Bush RS. et al. Role of radiation therapy in localized non-Hodgkin’s lymphoma. Radiother Oncol 1985; 4: 211-223
78 Reinartz G, Kardels B, Koch P. et al. University Of Muenster For The German Multicenter Study Group Of Gi.-Nhl Analysis of Failures after Whole Abdominal Irradiation in Gastrointestinal Lympomas. Is Prophylactic Irradiation of Inguinal Lymph Nodes Required?. Strahlenther Onkol 1999; 175: 601-605
79 Taal BG, Burgers JM, van Heerde P. et al. The clinical spectrum and treatment of primary non-Hodgkin’s lymphoma of the stomach. Ann Oncol 1993; 4: 839-846
80 Yahalom J, Illidge T, Specht L. et al. Modern Radiation Therapy for Extranodal Lymphomas: Field and Dose Guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol 2015; 9: 11-31
81 Rummel MJ, Niederle N, Maschmeyer G. et al. Bendamustine plus rituximab versus CHOP plus rituximabas first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381: 1203-1210
82 Fischbach W, Bornschein J, Hoffman JC. et al. Update S2k-Guideline Helicobacter pylori and gastroduodenal ulcer disease of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS). Z Gastroenterol 2024; 62: 261-321
83 Malfertheiner P, Megraud F, Rokkas T. et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut 2022; 1-39
84 Fischbach W, Goebeler-Kolve ME, Dragosics B. et al. Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication: experience from a large prospective series. GUT 2004; 53: 34-37
85 Wündisch T, Thiede C, Morgner A. et al. Long-Term Follow-Up of Gastric MALT Lymphoma After Helicobacter Pylori Eradication. J Clin Oncol 2005; 23 (31) 1-7
86 Fischbach W, Goebeler-Kolve M, Starostik P. et al. Minimal residual low-grade gastric MALT-type lymphoma after eradication of Helicobacter pylori. Lancet 2002; 360: 547-548
87 Fischbach W, Goebeler ME, Ruskone-Fourmestraux A. et al. Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be safely managed by a watch-and-wait strategy. Experience from a large international series. Gut 2007; 56: 1685-1687
88 Copie-Bergman C, Gaulard P, Lavergne-Slove A. et al. Proposal for a new histological grading system for post-treatment evaluation of gastric MALT lymphoma. Gut 2003; 52: 1656
89 Fischbach W, Dorlöchter C. Patients with gastric MALT lymphoma revealing persisting endoscopic abnormalities after successful eradication of Helicobacter pylori can be safely managed by a watch-and-wait strategy. Z Gastroenterol 2019; 57: 1-7
90 Raderer M, Streubel B, Wöhrer S. et al. Successful antibiotic treatment of Helicobacter pylori negative gastric mucosa associated lymphoid tissue lymphomas. Gut 2006; 55: 616-618
91 Al-Taie O, Al-Taie E, Fischbach W. Patients with Helicobacter pylori Negative Gastric Marginal Zone B-Cell Lymphoma (MZBCL) of MALT have a Good Prognosis. Z Gastroenterol 2014; 52: 1-5
92 Zullo A, Hassan C, Ridola L. et al. Eradication Therapy in Helicobacter pylori-negative, gastric low-grade Mucosa-associated Lymphoid Tissue lymphoma patients. A systematic Review. J Clin Gastroenterol 2013; 47 (10) 824-827
93 Morgner A, Miehlke S, Fischbach W. et al. Complete remission of primary high-grade B-cell gastric lymphoma after cure of Helicobacter pylori infection. J Clin Oncol 2001; 19: 2041-2048
94 Chen LT, Lin JT, Tai JJ. et al. Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma. J Natl Cancer Inst 2005; 97: 1345-1353
95 Kuo SH, Yeh KH, Wu MS. Helicobacter pylori eradication therapy is effective in the treatment of early-stage H. pylori-positive diffuse large B-cell lymphomas. Blood 2012; 119: 4838-3844
96 Capelle LG, Vries AC, Looman CWN. et al. Gastric MALT lymphoma: Epidemiology and high adenocarcinoma risk in a nation-wide study. Eur J Cancer 2008; 44: 2470-2476